Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Study:

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Rationale:

n/a

Purpose:

The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Advanced Solid Tumors
Neoplasms
Drug: ixabepilone
Drug: Rifampin
Phase 1

Verified by Bristol-Myers Squibb October, 2010

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov identifier: NCT00207090

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Bristol-Myers Squibb., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site